DEA suspends Class 1 Cardinal Health facility; GSK earmarks $64M for Australian expansion;

@FiercePharma: Could be big if it actually ends up working. RT @FierceMedDev: Depression diagnostic passes initial trial. Story | Follow @FiercePharma

> The Drug Enforcement Administration suspended the work at a Cardinal Health facility in Lakeland, FL, which deals with controlled substances, on allegations that some filled prescriptions were not written for legitimate medical reasons, the company said. Report

> GlaxoSmithKline ($GSK) plans to invest A$60 million ($64 million) into an expansion of its manufacturing and R&D operations in Victoria, Australia, creating 58 new jobs by 2017. More

> Shanghai Pharmaceuticals said it would buy a 70% stake in Changzhou Kony Pharm now, and the remaining 30% over the next two years, to boost its presence in active pharmaceutical ingredients. Release

> Valeant ($VRX) wrapped up the divestiture of several generic skin products to Mylan ($MYL), as required by the Federal Trade Commission as a condition of its purchase of Sanofi's ($SNY) dermatology business Dermik. Report

> Novartis ($NVS), which now owns the eye-care company Alcon, is sponsoring a program to improve ophthalmology in the U.K. via medical education, training and support. Story

> Questcor Pharmaceuticals reported street-beating fourth-quarter sales of $75 million, thanks to strong sales of its drug Acthar. Report

Biotech News

@FierceBiotech: Will $1B cancer IP theft suit trigger tighter vigilance on researchers' work? Article  | Follow @FierceBiotech

@JohnCFierce: So does BioLineRx see itself as a hep C co. now that it has in-licensed a 2nd program, or is this about share price? Release | Follow @JohnCFierce

@FierceMedDev: DNA-sequencing penetrates Norway's healthcare system. Story | Follow @FierceMedDev

@MarkHFierce: Dudes, eat lots of walnuts and your prostate cancer risk may shrink. It worked in mice, at least... More | Follow @MarkHFierce

> PhRMA's COPD pipeline report spotlights blockbuster hopefuls. Report

> Sanofi chief can't spark much enthusiasm for new MS drugs. More

> Merck steers top drug prospect to an NDA, analysts ponder R&D weakness. Article

> Amgen's Xgeva faces FDA skepticism. Item

Medical Device News

> Apollo Endosurgery secures $47.6M to launch surgical tools. News

> GAO report finds some hospitals paying more for devices. Report

> Smith & Nephew, Kensey Nash impress with earnings announcements. Article

> DNA-sequencing penetrates Norway's healthcare system. Story

> ALung scores $10M in Series B. News

IT News

> Researchers create software-based 3-D genome map. Story

> Supercomputing supports genetic, cancer research in Arizona. Article

> Median Technologies, Sanofi sign medical imaging deal. News

> Norway's sequencing project will need major IT infrastructure. More

> Oracle announces new round of projects in IT, clinical trials. Piece

And Finally... Long-term therapy with aspirin or warfarin delivered similar results in heart failure patients with normal heart rhythms, a study found. Report

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.